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Summary
Despite substantial progress in prevention of perinatal group B streptococcal (GBS) disease since the 1990s, GBS remains the 
leading cause of early-onset neonatal sepsis in the United States. In 1996, CDC, in collaboration with relevant professional soci-
eties, published guidelines for the prevention of perinatal group B streptococcal disease (CDC. Prevention of perinatal group B 
streptococcal disease: a public health perspective. MMWR 1996;45[No. RR-7]); those guidelines were updated and republished in 
2002 (CDC. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC. MMWR 2002;51[No. RR-11]). 
In June 2009, a meeting of clinical and public health representatives was held to reevaluate prevention strategies on the basis of 
data collected after the issuance of the 2002 guidelines. This report presents CDC’s updated guidelines, which have been endorsed 
by  the American College of Obstetricians and Gynecologists, the American Academy of Pediatrics, the American College of Nurse-
Midwives, the American Academy of Family Physicians, and the American Society for Microbiology. The recommendations were 
made on the basis of available evidence when such evidence was sufficient and on expert opinion when available evidence was 








Universal screening at 35–37 weeks’ gestation for maternal GBS colonization and use of intrapartum antibiotic prophylaxis has 
resulted in substantial reductions in the burden of early-onset GBS disease among newborns. Although early-onset GBS disease has 
become relatively uncommon in recent years, the rates of maternal GBS colonization (and therefore the risk for early-onset GBS 
disease in the absence of intrapartum antibiotic prophylaxis) remain unchanged since the 1970s. Continued efforts are needed to 
sustain and improve on the progress achieved in the prevention of GBS disease. There also is a need to monitor for potential adverse 
consequences	of	intrapartum	antibiotic	prophylaxis	(e.g.,	emergence	of	bacterial	antimicrobial	resistance	or	increased	incidence	or	
severity of non-GBS neonatal pathogens). In the absence of a licensed GBS vaccine, universal screening and intrapartum antibiotic 
prophylaxis continue to be the cornerstones of early-onset GBS disease prevention.
colonization with GBS in the genitourinary or gastrointestinal 
tracts is the primary risk factor for disease. Beginning in the 
mid 1980s, clinical trials and well-designed observational stud-
ies demonstrated that administering intravenous antibiotics 
during labor to women at risk for transmitting GBS to their 
newborns could prevent invasive disease in the first week of life 
(i.e., early-onset disease) (6–11). As a result of the collaborative 
efforts of clinicians, researchers, professional organizations, 
parent advocacy groups, and the public health community 
in the 1990s, recommendations for intrapartum prophylaxis 
to prevent perinatal GBS disease were issued in 1996 by the 
American College of Obstetricians and Gynecologists (ACOG) 
(12) and CDC (13) and in 1997 by the American Academy of 
Introduction
In the 1970s, the bacterium group B Streptococcus (GBS) 
emerged as the leading infectious cause of early neonatal mor-
bidity and mortality in the United States (1–4). Initial case 
series reported case-fatality ratios as high as 50% (5). Maternal 
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Pediatrics (AAP) (14). Revised guidelines for the prevention of 
early-onset GBS disease issued in 2002 recommended universal 
culture-based screening of all pregnant women at 35–37 weeks’ 
gestation to optimize the identification of women who should 
receive intrapartum antibiotic prophylaxis (15).
Before active prevention was initiated, an estimated 7,500 
cases of neonatal GBS disease occurred annually in the United 
States (16). Striking declines in disease incidence coincided 
with increased prevention activities in the 1990s (17), and a 
further reduction occurred following the issuance of the rec-
ommendation for universal screening in 2002 (18). However, 
GBS disease remains the leading infectious cause of morbidity 
and mortality among newborns in the United States (19,20). 
The continued burden of disease and newly available data rel-
evant to early-onset GBS disease prevention from the fields of 
epidemiology, obstetrics, neonatology, microbiology, molecular 
biology, and pharmacology prompted revision of the guidelines 
for early-onset GBS disease prevention.
Methods
In November 2008, CDC formed a technical working 
group* to revise the 2002 guidelines (15). The group consisted 
of representatives from the ACOG Committee on Obstetric 
Practice, the American College of Nurse-Midwives (ACNM), 
the AAP Committee on Infectious Diseases and Committee 
on the Fetus and Newborn, the American Academy of Family 
Physicians (AAFP), the Society for Healthcare Epidemiology 
of America, the American Society for Microbiology (ASM), 
and CDC’s Active Bacterial Core surveillance system, as well 
as experts in GBS epidemiology, clinical microbiology, and 
pharmacology. The group held regular telephone conference 
calls to identify potential areas of change in the recommenda-
tions to prevent GBS disease, and to define sources of newly 
available data (published and unpublished) to inform the 
revision of the guidelines.
The working group identified a subset of topics for in-depth 
review, including areas in which new technologies and/or 
evidence had become available since the publication of the 
2002 guidelines, areas in which implementation of the 2002 
guidelines was found to be suboptimal on the basis of pub-
lished and unpublished data, and areas in which interpretation 
of the 2002 guidelines was found to be variable on the basis 
of inquiries received at CDC and the experience of experts in 
the field. For these topics, a thorough review was conducted of 
published literature through PubMed searches, other sources 
(including abstracts and conference proceedings), and unpub-
lished data from ongoing surveillance and research activities 
of which the working group was aware. For topics on which 
several sources of data were available, evidence was summarized 
in tables. For topics on which relatively little new evidence 
was available, summaries of pertinent data were provided to 
working group members. Expert opinion was sought from 
working group members regarding topics on which no new 
evidence was available.
In June 2009, an in-person meeting of the technical working 
group was held to review available data and develop updated 
recommendations using an evidence-based approach when 
possible and relying on expert scientific opinion when sufficient 
data were lacking (Table 1). These updated guidelines replace 
CDC’s 2002 guidelines. They are intended for providers of 
prenatal, obstetric, and neonatal care; supporting microbiol-* A list of the members appears on page 32 of this report.
TABLE 1. Evidence-based rating system used to determine strength of recommendations
Category Definition Recommendation
Strength of recommendation
A Strong evidence for efficacy and substantial clinical benefit Strongly recommended
B Strong or moderate evidence for efficacy but only limited clinical benefit Generally recommended
C Insufficient evidence for efficacy or efficacy does not outweigh possible adverse consequences Optional
D Moderate evidence against efficacy or for adverse outcome Generally not recommended
E Strong evidence against efficacy or for adverse outcome Never recommended
Quality of evidence supporting recommendation
I Evidence from at least one well-executed randomized, controlled trial or one rigorously designed laboratory-based 
experimental study that has been replicated by an independent investigator
II Evidence from at least one well-designed clinical trial without randomization, cohort or case-controlled analytic 
studies (preferably from more than one center), multiple time-series studies, dramatic results from uncontrolled 
studies, or some evidence from laboratory experiments
III Evidence from opinions of respected authorities based on clinical or laboratory experience, descriptive studies, or 
reports of expert committees
Source: Adapted from LaForce FM. Immunizations, immunoprophylaxis, and chemoprophylaxis to prevent selected infections. US Preventive Services Task Force. 
JAMA 1987;257:2464–70.
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ogy laboratories, hospital administrators, and managed-care 
organizations; childbirth educators; public health authorities; 
and expectant parents and their advocates.
Invasive Group B Streptococcal 
Disease
Group B Streptococcus, or Streptococcus agalactiae, is a gram-
positive bacterium that causes invasive disease primarily in 
infants, pregnant or postpartum women (19,21–27), and older 
adults, with the highest incidence among young infants (19). 
Infections in newborns occurring within the first week of life 
are designated early-onset disease. Late-onset infections occur 
in infants aged >1 week, with most infections evident during 
the first 3 months of life. Because of the burden of disease 
among infants and the availability of effective interventions 
to prevent early-onset GBS disease, these guidelines concern 
only early-onset disease. The measures used to prevent early-
onset GBS disease also might prevent some perinatal maternal 
infections (17,28); however, they do not prevent late-onset 
infant disease (29).
Early-onset GBS Disease
GBS is the leading infectious cause of 
morbidity and mortality among infants in 
the United States. As a result of prevention 
efforts, incidence of GBS has declined dra-
matically over the past 15 years, from 1.7 
cases per 1,000 live births in the early 1990s 
to 0.34–0.37 cases per 1,000 live births in 
recent years (Figure 1). On the basis of data 
from CDC’s Active Bacterial Core surveil-
lance (ABCs) system, a network of 10 sites 
across the United States that conduct active, 
population-based surveillance, CDC esti-
mates that in recent years, GBS has caused 
approximately 1,200 cases of early-onset 
invasive disease per year (30); approximately 
70% of cases are among babies born at term 
(≥37 weeks’ gestation) (19).
Infants with early-onset GBS disease gener-
ally present with respiratory distress, apnea, 
or other signs of sepsis within the first 24–48 
hours of life (3,31). The most common 
clinical syndromes of early-onset disease are 
sepsis and pneumonia; less frequently, early-
onset infections can lead to meningitis. The 
case-fatality ratio of early-onset disease has 
declined from as high as 50% in the 1970s 
(5) to 4%–6% in recent years, primarily because of advances 
in neonatal care (17,19). Mortality is higher among preterm 
infants, with case-fatality rates of approximately 20% and as 
high as 30% among those ≤33 weeks’ gestation, compared 
with 2%–3% among full-term infants (17,19).
Early-onset infections are acquired vertically through 
exposure to GBS from the vagina of a colonized woman. 
Neonatal infection occurs primarily when GBS ascends from 
the vagina to the amniotic fluid after onset of labor or rupture 
of membranes, although GBS also can invade through intact 
membranes (32,33). GBS can be aspirated into the fetal 
lungs, which in turn can lead to bacteremia. Infants also can 
become infected with GBS during passage through the birth 
canal; infants who are exposed to the organism through this 
route can become colonized at mucus membrane sites in the 
gastrointestinal or respiratory tracts, but these colonized infants 
most commonly remain healthy.
Risk Factors for Early-onset GBS 
Disease
Maternal intrapartum GBS colonization is the primary risk 
factor for early-onset disease in infants. A classic prospective 
cohort study conducted during the 1980s revealed that preg-
nant women with GBS colonization were >25 times more likely 
FIGURE 1. Incidence of early- and late-onset invasive group B streptococcal (GBS) disease 
— Active Bacterial Core surveillance areas, 1990–2008, and activities for prevention of GBS 
disease
Abbreviations: ACOG = American College of Obstetricians and Gynecologists and AAP = American Acad-
emy of Pediatrics.
Source: Adapted from Jordan HT, Farley MM, Craig A, et al. Revisiting the need for vaccine prevention of 
late-onset neonatal group B streptococcal disease. Pediatr Infect Dis J 2008;27:1057–64.
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than pregnant women with negative prenatal cultures to deliver 
infants with early-onset GBS disease (34). In the absence of 
any intervention, an estimated 1%–2% of infants born to colo-
nized mothers develop early-onset GBS infections (13,34,35). 
Approximately 10%–30% of pregnant women are colonized 
with GBS in the vagina or rectum (36–38). GBS colonization 
during pregnancy can be transient, intermittent, or persistent 
(39–41). Although some women with GBS colonization during 
a pregnancy will be colonized during subsequent pregnancies, 
a substantial proportion will not (42,43). The gastrointestinal 
tract serves as the primary reservoir for GBS and is the likely 
source of vaginal colonization. Heavy colonization, defined as 
culture of GBS from direct plating rather than from selective 
broth only, is associated with higher risk for early-onset disease 
(44,45). GBS identified in clean-catch urine specimens dur-
ing any trimester is considered a surrogate for heavy maternal 
colonization and also is associated with a higher risk for early-
onset GBS disease (46–50).
In addition to maternal colonization with GBS, other factors 
that increase the risk for early-onset disease include gestational 
age <37 completed weeks, longer duration of membrane rup-
ture, intra-amniotic infection, young maternal age, black race, 
and low maternal levels of GBS-specific anticapsular antibody 
(51–58). Previous delivery of an infant with invasive GBS 
disease is a risk factor for early-onset disease in subsequent 
deliveries (59–62). In a 1985 report of predictors of early-onset 
disease, women with gestation <37 weeks, membrane rupture 
of >12 hours, or intrapartum temperature >99.5ºF (>37.5ºC) 
had 6.5 times the risk for having an infant with early-onset 
GBS disease compared with women who had none of these 
risk factors (34). Of note, women who had one of these risk 
factors but who had negative prenatal screening cultures were 
at relatively low risk for early-onset GBS disease (incidence: 
0.9 cases per 1,000 births) compared with women who were 
colonized prenatally but had none of the risk factors (incidence: 
5.1 cases per 1,000 births) (34).
Some observational studies have reported an association 
between early-onset GBS disease and certain obstetric pro-
cedures, such as the use of internal fetal monitoring devices 
(58,63) and more than five or six digital vaginal examinations 
after onset of labor or rupture of membranes (55,63). However, 
lack of randomization in observational studies can result in 
confounding, because certain procedures might be used more 
frequently in high-risk settings (64). Although concern has 
been raised about performing other obstetric procedures (e.g., 
membrane stripping and mechanical and/or pharmacologic 
cervical ripening) on GBS-colonized women, available data are 
not sufficient to determine whether these procedures are associ-
ated with an increased risk for early-onset disease (65,66).
Prevention of Early-onset Group B 
Streptococcal Disease
Intravenous Intrapartum Antibiotic 
Prophylaxis
The use of intravenous intrapartum antibiotic prophylaxis 
to prevent early-onset GBS disease in the infant was first 
studied in the 1980s. Clinical trials and well-designed obser-
vational studies found that intrapartum antibiotic prophylaxis 
reduced vertical transmission of GBS, as measured by infant 
colonization (6,8,11,67) or by protection against early-onset 
disease (6–11). Early trials suggested an efficacy of 100% for 
intrapartum antibiotic prophylaxis to prevent early-onset 
disease among infants born to women with GBS colonization 
(7,8,10,11). Subsequent observational studies have found the 
effectiveness to be 86%–89% among infants born to women 
who received intrapartum GBS prophylaxis (62,68).
Other strategies to reduce maternal colonization and verti-
cal transmission have been studied, including intramuscular 
intrapartum antibiotic prophylaxis (67), antenatal (oral or 
intramuscular) antibiotics (69–71), and chlorhexidine vagi-
nal wipes or douches (72–76); however, none has proven to 
be effective at preventing early-onset disease. Although some 
nonrandomized studies on chlorhexidine have yielded promis-
ing results (72,75), randomized clinical trials have found no 
protection against early-onset GBS disease or neonatal sepsis 
(76,77).
Intrapartum Antibiotic Prophylaxis Agents
The efficacy of both penicillin (10) and ampicillin (7) as 
intravenously administered intrapartum agents for the preven-
tion of early-onset neonatal GBS disease was demonstrated in 
clinical trials. Penicillin has a narrower spectrum of antimi-
crobial activity and therefore might be less likely to select for 
resistant organisms, although one clinical trial found that peni-
cillin and ampicillin administered intravenously intrapartum 
were associated equally with the presence of ampicillin-resistant 
gram-negative organisms on postpartum vaginal-perineal 
culture (78). The dosages of penicillin and ampicillin used for 
intrapartum GBS prophylaxis are aimed at achieving adequate 
levels in the fetal circulation and amniotic fluid rapidly while 
avoiding potentially neurotoxic serum levels in the mother 
or fetus (79–83). Although the exact duration of antibiot-
ics needed to prevent vertical transmission of GBS has been 
debated (84,85), beta-lactam antibiotics for GBS prophylaxis 
administered for ≥4 hours before delivery have been found to 
be highly effective at preventing vertical transmission of GBS 
(86) and early-onset GBS disease (68). Shorter durations of 
appropriate antibiotics might provide some protection; in 
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particular, colonization data suggest durations of ≥2 hours 
before delivery might confer some protection (86).
The efficacy of alternatives to penicillin or ampicillin that 
have been used to prevent early-onset GBS disease among 
infants born to penicillin-allergic mothers (including cefazolin, 
clindamycin, erythromycin, and vancomycin) has not been 
measured in controlled trials. Cefazolin has a relatively narrow 
spectrum of activity, similar pharmacokinetics and dynamics 
to penicillin and ampicillin, and achieves high intra-amniotic 
concentrations (87–89). However, an estimated 10% of per-
sons with penicillin allergy also have immediate hypersensitiv-
ity reactions to cephalosporins (90). In contrast, data on the 
ability of clindamycin, erythromycin and vancomycin to reach 
bactericidal levels in the fetal circulation and amniotic fluid 
are very limited; available data suggest that erythromycin and 
clindamycin provided to pregnant women do not reach fetal 
tissues reliably (91–95).
Safety
Maternal anaphylaxis associated with GBS intrapartum 
chemoprophylaxis occurs but is sufficiently rare that any mor-
bidity associated with anaphylaxis is offset greatly by reductions 
in the incidence of maternal and neonatal invasive GBS disease. 
Anaphylaxis-related mortality is likely to be a rare event because 
the majority of women receiving intrapartum antibiotics will 
be in hospital settings where rapid intervention is readily avail-
able. Allergic reactions occur in an estimated 0.7%–4.0% of all 
treatment courses with penicillin, the most common of which 
is a maculopapular rash (96). Estimates of the rate of anaphy-
laxis caused by penicillin range from four per 10,000 to four 
per 100,000 recipients (96). Maternal anaphylaxis associated 
with GBS prophylaxis was reported in the early 1990s (97); 
since the release of the 1996 guidelines, four reports of nonfatal 
cases of anaphylaxis associated with GBS chemoprophylaxis in 
the United States have been published (98–101). In a CDC 
multistate sample of approximately 5,000 live births occurring 
during 1998–1999, a single, nonfatal anaphylactic reaction 
was noted among the 27% of deliveries in which intrapartum 
antibiotics were administered (62). In that case, a single dose 
of penicillin was administered approximately 4 hours before 
a preterm cesarean delivery, and an anaphylactic reaction 
occurred shortly after the mother received a single dose of a 
cephalosporin following umbilical cord clamping. A similar 
sample of approximately 7,600 live births occurring during 
2003–2004 revealed no cases of anaphylaxis among the 32% 
of deliveries in which mothers received intrapartum antibiotic 
prophylaxis for GBS (102).
Because a fetus or newborn is unlikely to have had a previous 
exposure to the antibiotic, and because specific maternal IgE 
antibodies are not transmitted across the placenta (103), there 
is no risk for anaphylaxis in the fetus or newborn resulting 
from intrapartum antibiotic prophylaxis. Although limited 
data are available on the impact of intrapartum antibiotics 
on neonatal gastrointestinal flora, one study comparing stool 
from infants born to women who received intrapartum GBS 
prophylaxis with stool from infants whose mothers received 
no intrapartum antibiotics found no significant difference in 
colonization with antibiotic-resistant enterobacteria between 
the two groups (104).
Antibiotic Resistance of GBS
The widespread use of intrapartum antibiotic prophylaxis to 
prevent early-onset GBS disease has raised concern about the 
development of antibiotic resistance among GBS isolates. GBS 
continues to be susceptible to penicillin, ampicillin, and first-
generation cephalosporins (19,105–109). However, isolates 
with increasing minimum inhibitory concentrations (MICs) 
to penicillin or ampicillin have been reported, including 14 
noninvasive isolates during 1995–2005 among adults in Japan 
(110), and 11 (0.2%) of 5,631 invasive isolates recovered dur-
ing 1999–2005 from patients of varying ages in the United 
States (111). Alterations in a penicillin-binding protein (PBP 
2X) were found in all of the isolates from Japan and four of 
those from the United States. The measured MICs from the 11 
invasive isolates from the United States are just at the threshold 
of susceptibility (≤0.12 µg/ml for penicillin and ≤0.25 µg/ml 
for ampicillin) (112), but the clinical significance of these MIC 
values is as yet unclear.
Relatively elevated MICs to cefazolin (1 µg/ml) also were 
reported among three (0.05%) of 5,631 invasive GBS iso-
lates collected through CDC’s active surveillance during 
1999–2005; two of the three isolates also had elevated MICs 
to penicillin (0.12 µg/ml) (111). Although Clinical and 
Laboratory Standards Institute guidelines do not specify sus-
ceptibility breakpoints for cefazolin, they recommend that all 
isolates susceptible to penicillin be considered susceptible to 
cefazolin (112). As with the elevated MICs to penicillin and 
ampicillin, the clinical significance of higher MICs to cefazolin 
among GBS isolates remains unclear.
The proportions of GBS isolates with in vitro resistance to 
clindamycin or erythromycin have increased over the past 20 
years. The prevalence of resistance among invasive GBS isolates 
in the United States ranged from 25% to 32% for erythromycin 
and from 13% to 20% for clindamycin in reports published 
during 2006–2009 (19,106,108). Resistance to erythromycin 
is associated frequently but not always with resistance to clin-
damycin. One longitudinal study of GBS early-onset sepsis 
found that although the overall rate of GBS early-onset disease 
declined over time, erythromycin-resistant GBS caused an 
increasing proportion of disease during this interval; however, 
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the incidence of antibiotic-resistant GBS early-onset sepsis 
remained stable (105).
Vaccines to Prevent GBS Disease
GBS vaccines have been investigated as a tool for reduc-
ing maternal colonization and preventing transmission to 
neonates (113,114); however, no licensed vaccine is available 
currently. Sufficient amounts of GBS capsular polysaccharide 
type-specific serum IgG in mothers have been shown to protect 
against invasive disease in their infants (51,115–118). Phase 
I and II clinical trials among healthy, nonpregnant adults of 
monovalent polysaccharide-protein conjugate vaccines of GBS 
disease-associated types have shown these vaccines to be well 
tolerated and immunogenic (116–121). A recent, double-blind 
randomized trial of a conjugate vaccine against GBS serotype 
III among nonpregnant women of reproductive age found a 
significant delay in acquisition of colonization with the vaccine-
serotype among vaccine recipients (122). Although an effective 
GBS vaccine would be a powerful tool against GBS disease, 
no licensed vaccine is yet available.
Identification of Candidates for 
Intrapartum Antibiotic Prophylaxis
Culture- Versus Risk-Based Screening
Early guidelines recommended the use of one of two 
approaches to identifying women who should receive intra-
partum antibiotic prophylaxis: a risk-based approach or a 
culture-based screening approach (13). Providers using the 
risk-based method identified candidates for intrapartum 
chemoprophylaxis according to the presence of any of the 
following intrapartum risk factors: delivery at <37 weeks’ gesta-
tion, intrapartum temperature ≥100.4ºF (≥38.0ºC), or rupture 
of membranes for ≥18 hours. Providers using the culture-based 
screening method screened all pregnant women for vaginal and 
rectal GBS colonization between 35 and 37 week’s gestation. 
Colonized women were offered intrapartum antibiotics at the 
time of labor onset or rupture of membranes if before labor. 
Under both strategies, intrapartum antibiotic prophylaxis was 
recommended for women with GBS bacteriuria at any time 
during their current pregnancy or for women who had given 
birth previously to an infant with invasive early-onset GBS 
disease.
A large population-based study conducted during 1998–
1999 demonstrated the superiority of culture-based screening 
over the risk-based approach to prevention of early-onset GBS 
disease (62). The study found that culture-based screening 
resulted in the identification of a greater proportion of women 
at risk for transmitting GBS to their newborns. Furthermore, 
women with a positive antenatal GBS culture were more 
likely to receive intrapartum antibiotic prophylaxis than those 
women with a risk-based indication for chemoprophylaxis. In 
2002, CDC’s guidelines for GBS prevention were updated to 
recommend universal culture-based screening to determine 
which women should receive intrapartum GBS chemoprophy-
laxis (15). CDC recommended that women with unknown 
GBS colonization status at the time of delivery be managed 
according to the presence of intrapartum risk factors.
Preterm Delivery
Because preterm (at <37 weeks and 0 days’ gestation) deliv-
ery is an important risk factor for early-onset GBS disease, 
and because assessing whether preterm labor or rupture of 
membranes will result in preterm delivery can be difficult, 
management of intrapartum antibiotic prophylaxis for women 
with threatened preterm delivery is challenging. Assessing the 
need for intrapartum prophylaxis for these women also can 
be difficult because GBS colonization status often is unknown 
when labor or rupture of membranes occur before 35–37 
weeks’ gestation. In addition, appropriate use of antibiotic 
prophylaxis for women with threatened preterm delivery is 
critical. For women remote from term with premature rupture 
of membranes, clinical trials have demonstrated that certain 
antibiotic regimens prolong latency (123,124). However, data 
from clinical trials also have suggested that certain antibiotics 
administered for preterm premature rupture of membranes 
can be associated with necrotizing enterocolitis in the neonate 
(125,126) and that antibiotics administered in the setting of 
spontaneous preterm labor can be associated with adverse 
neonatal outcomes, such as increased need for supplementary 
oxygen (127) or cerebral palsy (128).
The 2002 guidelines recommended that if GBS coloniza-
tion status from the current pregnancy is not known, and if 
onset of labor or rupture of membranes occurred before 37 
weeks’ gestation with a substantial risk for preterm delivery, 
then GBS screening should be performed and intrapartum 
antibiotic prophylaxis for GBS should be provided pending 
culture results. The implementation of those recommenda-
tions has been suboptimal, with limited GBS screening on 
hospital admission and limited administration of intrapartum 
antibiotic prophylaxis (102). However, when penicillin, ampi-
cillin, or cefazolin prophylaxis was administered for ≥4 hours 
before delivery to women delivering at <37 weeks’ gestation, 
antibiotic prophylaxis was 78% (95% confidence interval: 
44%–91%) effective in preventing early-onset GBS disease 
(CDC, unpublished data, 2009). No data are available on 
the effectiveness of antibiotics given before the intrapartum 
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period in GBS-colonized women with preterm premature 
rupture of membranes for preventing early-onset GBS disease 
in the infant.
Bacteriuria
GBS is found in the urine of 2%–7% of pregnant women 
(46–48,129,130). GBS bacteriuria in a pregnant woman is 
a marker for heavy genital tract colonization, and maternal 
GBS bacteriuria (including pure and predominant growth of 
GBS in the urine) has been associated with GBS colonization 
and an increased risk for early-onset disease in the newborn 
(46–50,129). Although some women receive antibiotics to 
treat GBS bacteriuria during pregnancy, antibiotics do not 
eliminate GBS from the genitourinary and gastrointestinal 
tracts, and recolonization after a course of antibiotics is typical 
(71,131,132). Studies have found that some women with GBS 
bacteriuria during the first trimester might not have vaginal-
rectal colonization detected at 35–37 weeks’ gestation (130) or 
at the time of delivery (133). However, maternal GBS bacte-
riuria at any point during pregnancy is a recognized risk factor 
for early-onset GBS disease and therefore has been included 
as an indication for intrapartum antibiotic prophylaxis since 
1996 (13,15).
The 1996 guidelines did not specify a colony-count thresh-
old for defining GBS bacteriuria. In 2002, the guidelines 
recommended that laboratory personnel report GBS present 
in any concentration in the urine. Most data on the risk for 
early-onset GBS disease among infants born to women with 
GBS bacteriuria are derived from studies of significant GBS 
bacteriuria (generally >105 colony-forming units per millimeter 
of urine) (47–49). Although lower concentrations (<104 cfu/
ml) of GBS in the urine can be associated with vaginal-rectal 
colonization (134), relatively few data are available on the risk 
for early-onset GBS disease among infants born to women 
with low colony-count GBS bacteriuria (48). One study 
from a vertically integrated health system in Utah found an 
elevated risk for early-onset GBS disease among infants born 
to women with low colony-count GBS bacteriuria compared 
with those whose mothers did not have GBS bacteriuria (135). 
However, because the majority of pregnant women in the study 
population had no urine culture performed, those with urine 
culture results might have been a biased subset. Therefore, the 
findings on women with low colony-count bacteriuria in this 
study might not be generalizable to all pregnant women with 
low colony-count bacteriuria. The recommendation to report 
any colony count of GBS in the urine represents increased 
workload for clinical microbiology laboratories, which gener-
ally do not report bacterial growth in urine of other pathogens 
at concentrations <104 cfu/ml (136) and rarely know whether 
urine samples are from pregnant women; as a result, some 
laboratories search for any GBS colonies in urine cultures from 
all women of reproductive age. Routine screening for asymp-
tomatic bacteriuria is recommended in pregnant women (137); 
the identification of GBS through this screening represents 
an opportunity to detect women at high risk for transmitting 
GBS to their infant. However, in the context of universal late 
antenatal GBS screening, it is unclear how much additional 
disease is prevented by screening for low colony-count GBS 
bacteriuria and whether identification of low colony-count 
bacteriuria is cost-effective.
Cesarean Delivery Performed Before 
Labor onset on a Woman With Intact 
Amniotic Membranes
Cesarean delivery does not prevent mother-to-child trans-
mission of GBS because GBS can cross intact amniotic 
membranes (32,33). A risk does exist for transmission of 
GBS from a colonized mother to her infant during a cesarean 
delivery. However, a retrospective study at a single hospital 
(138), a national population-based study from Sweden (139), 
and a review of CDC active, population-based surveillance 
data (CDC, unpublished data, 1998–1999 and 2003–2004) 
indicated that when a cesarean delivery is performed before 
onset of labor on a woman with intact amniotic membranes, 
the risk for early-onset GBS disease among full-term infants is 
extremely low. Data on risk for transmission to preterm infants 
born via cesarean delivery performed before onset of labor on a 
woman with intact amniotic membranes are limited; however, 
the risk for transmission is likely much lower than in the set-
ting of vaginal delivery or cesarean delivery following rupture 
of membranes or onset of labor.
Specimen Collection and 
Processing for GBS Screening
timing of Screening
Because GBS colonization status can change over the course 
of a pregnancy, the timing of specimen collection for determi-
nation of colonization status is important. Because coloniza-
tion can be transient, colonization early in pregnancy is not 
predictive of early-onset GBS disease (44). Late third trimester 
colonization status has been used as a proxy for intrapartum 
colonization (140). The negative predictive value of GBS 
cultures performed ≤5 weeks before delivery is 95%–98%; 
however, the clinical utility decreases when a prenatal culture 
is performed more than 5 weeks before delivery because the 
negative predictive value declines (37).
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Specimen Collection
Swabbing both the lower vagina and rectum (through the 
anal sphincter) increases the culture yield substantially com-
pared with sampling the cervix or the vagina without also swab-
bing the rectum (40,141–146). Although a small number of 
studies have examined the ability of perianal or vaginal-perianal 
cultures to detect GBS colonization (147,148), the available 
data on their performance compared with vaginal-rectal cul-
tures are limited. Studies have indicated that when women in 
the outpatient clinic setting collect their own vaginal-rectal 
screening specimens, with appropriate instruction, GBS yield 
is similar to when specimens are collected by a health-care 
provider (149–152).
The use of appropriate transport media can help sustain 
the viability of GBS in settings where immediate laboratory 
processing is not possible (153,154). GBS isolates can remain 
viable in transport media for several days at room temperature; 
however, the recovery of isolates declines during 1–4 days, par-
ticularly at high temperatures. Even when appropriate transport 
media are used, the sensitivity of culture is greatest when the 
specimen is stored at 4°C before culture and processed within 
24 hours of collection (139,155–157).
Specimen Processing
Regardless of the test selected to identify GBS, use of an 
enrichment broth improves detection substantially. When 
direct agar plating is used instead of selective enrichment 
broth, as many as 50% of women who are GBS carriers have 
false-negative culture results (143,144,158,159). Examples 
of selective enrichment broths include Todd-Hewitt broth 
supplemented either with gentamicin (8 µg/ml) and nalidixic 
acid (15 µg/ml) [TransVag broth] or with colistin (10 µg/ml) 
and nalidixic acid (15 µg/ml) [Lim broth] (160). Although 
TransVag and Lim broth media are often available without 
blood, the addition of 5% sheep blood can increase the 
recovery of GBS (161). Selective enrichment broth also can 
contain chromogenic substrates that provide for a change in 
color in the setting of beta-hemolytic GBS. Such broths can 
facilitate the identification of beta-hemolytic GBS; however, 
nonhemolytic isolates will not be detected by these broths 
alone (162–168). Among 265 GBS isolates from invasive 
early-onset cases that occurred in the 10 ABCs system areas 
during 2006–2008, a total of 4% were nonhemolytic (CDC, 
unpublished data, 2006–2008).
Following enrichment, the conventional means for identify-
ing GBS is through isolation on subculture to blood agar plates 
and presumptive identification by the CAMP test (169) or 
serologic identification using latex agglutination with group B 
streptococcal antisera (170). More recently, chromogenic agars 
that undergo color change in the presence of beta-hemolytic 
colonies of GBS have become available (171,172). As with 
pigmented enrichment broths, these chromogenic agars can 
facilitate detection of beta-hemolytic GBS, but the majority 
will not detect nonhemolytic strains. In addition more rapid 
techniques for identifying GBS directly from enrichment 
broth, or after subculture have been developed, including DNA 
probes (173–176) and nucleic acid amplification tests (NAAT) 
such as polymerase chain reaction (177,178).
Published studies on the performance of commercially 
available NAAT on nonenriched samples have demonstrated 
varying sensitivities (range: 62.5%–98.5%) and specificities 
(range: 64.5%–99.6%) compared with the gold standard of 
enrichment followed by subculture (179–188) (Table 2). Three 
studies have compared both intrapartum NAAT on nonen-
riched samples and late antepartum enriched culture results to 
intrapartum enriched culture (179,182,185). When comparing 
swabs collected at the two different time points, two of the 
studies found intrapartum NAAT to be slightly more sensitive 
(95.8% and 90.7%, respectively) than antepartum culture 
(83.3% and 84.3%, respectively) (182,185), although with 
widely overlapping confidence intervals. One study reported 
a statistically significant difference between the sensitivity of 
swabs collected intrapartum and tested with NAAT (94.0%) 
compared with enriched culture performed on swabs collected 
prenatally (54.3%) (179). The sensitivity of NAAT for GBS 
increases to 92.5%–100.0% with use of an enrichment step 
before testing the sample (177,178,188). Use of an enrichment 
step lengthens the time to obtain a final result; however, for 
antenatal testing, the accuracy of results is much more impor-
tant than timeliness.
Despite the availability of NAAT for GBS, utility of such 
assays in the intrapartum setting remains limited. Although a 
highly sensitive and specific test with rapid turnaround time 
could be used to assess intrapartum GBS colonization and 
therefore obviate the need for antenatal screening, data on 
currently available assays do not support their use in replace-
ment of antenatal culture or risk-based assessment of women 
with unknown GBS status on admission for labor. The addi-
tional time required for enrichment of samples makes it not 
feasible for intrapartum testing, and the sensitivity of assays 
in the absence of enrichment is not adequate in comparison 
to culture. In addition, concerns remain regarding real-world 
turnaround time, test complexity, availability of testing at all 
times, staffing requirements, and costs. In settings that can 
perform NAAT, such tests might prove useful for the limited 
circumstance of a woman at term with unknown colonization 
status and no other risk factors. Even optimal NAAT would 
have drawbacks in the intrapartum setting, including a delay 
in administration of antibiotics while waiting for the result, 
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and no antimicrobial susceptibility testing for penicillin-allergic 
women. Other rapid tests in addition to NAAT have been 
developed to detect GBS rapidly from nonenriched samples, 
including optical immunoassays and enzyme immunoassays; 
however, none is sufficiently sensitive when used on a direct 
specimen to detect GBS colonization reliably in the intrapar-
tum setting (180,189–192).
Antimicrobial Susceptibility testing
Antimicrobial susceptibility testing of GBS isolates is crucial 
for appropriate antibiotic prophylaxis selection for penicillin-
allergic women who are at high risk for anaphylaxis because 
resistance to clindamycin, the most common agent used in 
this population, is increasing among GBS isolates. In addi-
tion, appropriate methodologies for susceptibility testing 
are important because inducible clindamycin resistance can 
occur in some strains that appear susceptible in broth suscep-
tibility tests (193,194). D-zone testing using the double-disk 
diffusion method has been used to identify isolates that are 
erythromycin-resistant and clindamycin-susceptible, yet have 
inducible resistance to clindamycin (195). Isolates that are 
D-zone positive are considered to have inducible clindamycin 
TABLE 2. Performance of Nucleic Acid Amplification Tests* (NAAT) compared with enriched culture for detecting group B Streptococcus (GBS)













NAAT performed on nonenriched samples
IDI-Strep§ IP VR 140/149 94.0% 626/653 95.9%
IDI-Strep¶ IP V 35/56 62.5% 252/259 97.3%
IDI-Strep** AP/IP VR 59/68 86.8% 157/165 95.2%
GeneXpert†† IP VR 23/24 95.8% 20/31 64.5%
IDI-Strep§§ AP/IP VR 149/188 79.3% 575/603 95.4%
GeneXpert§§ AP/IP VR 173/190 91.1% 570/594 96.0%
BD GeneOhm¶¶ AP V 64/83 77.1% 99/117 84.6%
BD GeneOhm*** IP VR 49/54 90.7% 121/124 97.6%
GeneXpert††† AP/IP V 135/137 98.5% 723/726 99.6%
IDI-Strep§§§ IP VR 38/42 90.5% 148/154 96.1%
NAAT performed on enriched¶¶¶ samples
BD GeneOhm**** AP VR 49/53 92.5% 136/147 92.5%
BD GeneOhm†††† AP VR §§§§ 100.0% §§§§ 99.3%
BD GeneOhm†††† AP VR §§§§ 92.5% §§§§ 99.3%
BD GeneOhm¶¶¶¶ AP V/VR 136/141 96.4% 349/357 97.8%
Abbreviations: AP = antepartum, IP = intrapartum, V = vaginal only, and VR = vaginal-rectal.
 * Includes only those NAAT that are approved for use by the Food and Drug Administration.
 † Compared with enriched culture of specimen collected at the same time as that used for NAAT.
 § Source: Davies HD, Miller MA, Faro S, Gregson D, Kehl SC, Jordan JA. Multicenter study of a rapid molecular-based assay for the diagnosis of group B Streptococcus 
colonization in pregnant women. Clin Infect Dis 2004;39:1129–35.
 ¶ Source: Aziz N, Baron EJ, D’Souza H, Nourbakhsh M, Druzin ML, Benitz WE. Comparison of rapid intrapartum screening methods for group B streptococcal vaginal 
colonization. J Matern Fetal Neonatal Med 2005;18:225–9.
 ** Source: Atkins KL, Atkinson RM, Shanks A, Parvin CA, Dunne WM, Gross G. Evaluation of polymerase chain reaction for group B Streptococcus detection using an 
improved culture method. Obstet Gynecol 2006;108(3 Pt 1):488–91.
 †† Source: Gavino M, Wang E. A comparison of a new rapid real-time polymerase chain reaction system to traditional culture in determining group B Streptococcus 
colonization. Am J Obstet Gynecol 2007;197:388e1–4.
 §§ Source: Edwards RK, Novak-Weekley SM, Koty PP, Davis T, Leeds LJ, Jordan JA. Rapid group B streptococci screening using a real-time polymerase chain reaction 
assay. Obstet Gynecol 2008;111:1335–41.
 ¶¶ Source: Smith D, Perry JD, Laine L, Galloway A, Gould FK. Comparison of BD GeneOhm real-time polymerase chain reaction with chromogenic and conventional 
culture methods for detection of group B Streptococcus in clinical samples. Diagn Microbiol Infect Dis 2008;61:369–72.
 *** Source: Money D, Dobson S, Cole L, et al. An evaluation of a rapid real time polymerase chain reaction assay for detection of group B Streptococcus as part of a 
neonatal group B Streptococcus prevention strategy. J Obstet Gynaecol Can 2008;30:770–5.
 ††† Source: El Helali N, Nguyen JC, Ly A, Giovangrandi Y, Trinquart L. Diagnostic accuracy of a rapid real-time polymerase chain reaction assay for universal intrapartum 
group B Streptococcus screening. Clin Infect Dis 2009;49:417–23.
 §§§ Source: Alfa MJ, Sepehri S, De Gagne P, Helawa M, Sandhu G, Harding GK. Real-time PCR assay provides reliable assessment of intrapartum carriage of group B 
Streptococcus. J Clin Microbiol 2010;48:3095–9.
 ¶¶¶ Duration of incubation in selective enrichment broth varied (range: 4–24 hours).
 **** Source: Goodrich JS, Miller MB. Comparison of culture and 2 real-time polymerase chain reaction assays to detect group B Streptococcus during antepartum 
screening. Diagn Microbiol Infect Dis 2007;59:17–22.
 †††† Source: Block T, Munson E, Culver A, Vaughan K, Hryciuk JE. Comparison of carrot broth- and selective Todd-Hewitt broth-enhanced PCR protocols for real-time 
detection of Streptococcus agalactiae in prenatal vaginal/anorectal specimens. J Clin Microbiol 2008;46:3615–20.
 §§§§ Primary data unavailable.
 ¶¶¶¶ Source: Scicchitano L, Bourbeau P. Comparative evaluation of the AccuProbe group B Streptococcus culture test, the BD GeneOhm Strep B assay, and culture for 
detection of group B streptococci in pregnant women. J Clin Microbiol 2009;47:3021–3.
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resistance and are presumed to be resistant although the clinical 
significance of this resistance is not clear (196).
Secondary Prevention of 
Early-onset GBS Among Infants
Currently available GBS prevention strategies will not pre-
vent all cases of early-onset disease. Rapid detection of neonatal 
infections and initiation of appropriate treatment is needed 
to minimize morbidity and mortality among the cases that 
continue to occur. The detection of early-onset GBS disease 
poses certain clinical challenges, because neonatal providers 
must take into account the clinical appearance of the infant, 
the presence of maternal risk factors for GBS disease, and infant 
exposure to intrapartum antibiotics.
Infants with Signs of Sepsis
As use of intrapartum antibiotics to prevent early-onset GBS 
disease increased, concern was expressed that signs of sepsis in 
the newborn could be delayed or masked, impairing the abil-
ity of clinicians to detect early-onset GBS disease (197–199). 
However, several studies conducted since 1996 have found no 
significant difference in the clinical presentation of early-onset 
GBS disease between infants exposed to intrapartum antibiot-
ics and those not exposed (200–204). Approximately 90% of 
cases of early-onset disease continue to manifest within the 
first 24 hours of life.
Although maternal GBS colonization might increase clinical 
suspicion for early-onset GBS disease in an infant, in the era 
of universal screening, >60% of early-onset GBS cases have 
occurred among infants born to women who had a negative pre-
natal GBS culture screen (102,203,204). False-negative cases are 
not unexpected because culture at 35–37 weeks’ gestation will 
fail to detect some women with intrapartum GBS colonization. 
As effective prevention strategies are increasingly implemented, 
a growing proportion of the remaining relatively low burden of 
disease will reflect inherent limitations in the strategies. Signs of 
sepsis in any newborn can be an indication of early-onset GBS 
disease, regardless of maternal colonization status.
Among infants with signs of early-onset disease, the detection 
of GBS can be increased by performing culture of both blood 
and cerebrospinal fluid (CSF). Blood cultures can be sterile in 
as many as 15%–33% of newborns with meningitis (205–209), 
and the clinical management of an infant with abnormal CSF 
findings differs from that of an infant with normal CSF.
Infants Born to Women 
with Chorioamnionitis
Chorioamnionitis is an important risk factor for early-
onset GBS disease in women with GBS colonization and 
can reflect an intrauterine onset of infection in the neonate 
(45,63,210–212). Intrapartum fever, one sign of chorioamni-
onitis in parturient women, has been associated with failure of 
intrapartum antibiotics to prevent GBS disease in the newborn 
(68,213). Intrapartum treatment of chorioamnionitis can 
prevent neonatal sepsis (214,215). The diagnosis of chorio-
amnionitis usually is made clinically on the basis of signs and 
symptoms such as fever (which might be low-grade), uterine 
tenderness, fetal tachycardia, maternal tachycardia, and foul-
smelling or purulent amniotic fluid. In an effort to avert neo-
natal infections, maternal fever alone in labor may be used as 
a sign of chorioamnionitis and hence indication for antibiotic 
treatment, particularly among women with a significant risk 
factor for chorioamnionitis (e.g., prolonged labor or prolonged 
rupture of membranes).
Because an association has been observed between epi-
dural labor analgesia and fever, chorioamnionitis might be 
overdiagnosed in women with epidurals, which could lead to 
unnecessary diagnostic evaluations and unnecessary exposure 
to empirical antibiotics in neonates (216). However, multistate 
surveillance data suggest that although epidural use is com-
mon (in 67% of births), intrapartum temperature of ≥100.4ºF 
[≥38.0ºC] (3.3% of births) and physician diagnoses of cho-
rioamnionitis (3.1% of births) remain relatively rare (102) 
(CDC, unpublished data, 2009). Consultation with obstetric 
providers to determine whether chorioamnionitis is suspected 
is important for guiding neonatal management.
Well-Appearing Infants Exposed to 
Inadequate Intrapartum Antibiotics
The management of well-appearing infants whose moth-
ers received inadequate intrapartum antibiotic prophylaxis 
(because of either a short duration of exposure before delivery 
or use of an agent with limited efficacy data) can be challeng-
ing. Previous GBS prevention guidelines have recommended 
that infants whose mothers received inadequate intrapartum 
antibiotic prophylaxis and those <35 weeks’ gestational age 
exposed to intrapartum antibiotics be evaluated with a blood 
culture and complete blood count (CBC) with differential 
(13,15). There are limitations to this diagnostic approach. 
The sensitivity of blood culture can be low among newborns 
exposed to intrapartum antibiotics (217,218). Available data 
on the performance of the CBC as a screening test for neonatal 
sepsis suggest that although the negative predictive value is 
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high, the positive predictive value is low, particularly among 
healthy-appearing term infants (219–221). The sensitivity of 
the CBC is lowest immediately after birth, and its performance 
as a screen for sepsis can be improved by obtaining the blood 
specimen between 6–12 hours of life (220,222,223). Clinical 
signs of sepsis have been found to be a more sensitive indicator 
of neonatal sepsis than hematologic tests (201).
Certain centers provide intramuscular penicillin to asymp-
tomatic infants within 1 hour of birth; this practice is based 
on results of observational studies demonstrating declines in 
early-onset GBS disease coincident with a policy of univer-
sal administration of intramuscular penicillin to newborns 
(224–226). However, because the studies used historic control 
groups and were conducted at a single center that does not 
screen pregnant women routinely for antenatal GBS coloniza-
tion, the findings are not generalizable to other settings.
Implementation and Impact 
of GBS Prevention Efforts
Implementation of the 2002 
Guidelines
After the issuance of the 2002 recommendation for universal 
culture screening, implementation was rapid and widespread. 
The most robust evaluation comes from a multistate, popula-
tion-based analysis of 819,000 live births during 2003–2004 
(102) and a similarly designed study 
of births during 1998–1999 (62). The 
proportion of infants whose mothers 
were screened for GBS colonization 
before delivery increased from 48.1% 
during 1998–1999 to 85.0% during 
2003–2004 (Figure 2); among women 
screened during 2003–2004, a total of 
98.4% had a result available at labor. 
Among screened women, 24.2% were 
documented as GBS-positive, within 
the range of expected colonization 
rates. The proportion of mothers with 
an indication for intrapartum antibiotic 
prophylaxis who received them also 
increased substantially, from 73.8% 
during 1998–1999 to 85.1% during 
2003–2004 (Figure 3).
Despite widespread uptake of uni-
versal screening, implementation fell 
short in several key areas. Infants born 
preterm have an elevated risk for early-
onset disease, and because antenatal 
screening is recommended at 35–37 weeks of gestation, only 
50.3% of women delivering preterm had a known coloniza-
tion status at the time of hospital admission. Although it is 
recommended that women with unknown GBS status who 
deliver preterm receive intrapartum antibiotic prophylaxis, 
only 63.4% received prophylaxis. In addition, intrapartum 
antibiotic prophylaxis administration for the indications of 
GBS bacteriuria or having delivered a previous infant with 
GBS disease was also low (73.5%) among preterm deliveries. 
Intrapartum antibiotic prophylaxis was provided to a greater 
proportion (84.5%) of women delivering preterm who had a 
positive GBS screening result. Screening for GBS on admission 
among women with threatened preterm delivery and unknown 
colonization status was suboptimal; only 18% of women 
who progressed to delivery and 31% of women who did not 
progress to delivery were screened despite a recommendation 
to perform cultures for GBS at hospital admission for this 
population (15,102).
As anticipated, the proportion of laboring women who 
received intrapartum antibiotics increased only slightly, from 
26.8% to 31.7%, under universal screening. Penicillin and 
ampicillin, the recommended agents for intrapartum GBS pro-
phylaxis for women with no allergy to penicillin, remained the 
most common agents administered (76.7% of women receiv-
ing intrapartum antibiotic prophylaxis received these agents). 
However, among penicillin-allergic women, the agents most 
often administered did not reflect the 2002 recommendations. 
FIGURE 2. Percentage of pregnant women screened for group B streptococcal colonization 
— Active Bacterial Core surveillance areas, 1998–1999 and 2003–2004*
Source: Van Dyke MK, Phares CR, Lynfield R, Thomas AR, Arnold KE, Craig AS, et al. Evaluation of universal 
antenatal screening for group B Streptococcus. N Engl J Med 2009;360:2626–36.
* Reported values are weighted to account for the stratified survey design. The number of charts abstracted 
was 5,144 for 1998–1999 and 7,691 for 2003–2005.
† 95% confidence inerval.
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In particular, only 13.8% of penicillin-allergic women who 
were not at high risk for anaphylaxis received cefazolin, despite 
a recommendation that this more effective agent be used. 
Clindamycin remained the leading agent among penicillin-
allergic women (69.9% of those at low risk for anaphylaxis 
and 83.5% of those at high risk). Among women receiving 
clindamycin for prophylaxis, clindamycin and erythromycin 
susceptibility testing were performed rarely despite recommen-
dations that susceptibility testing be conducted on all vaginal-
rectal specimens from women who are allergic to penicillin and 
at high risk for anaphylaxis (15,102). A single-hospital study 
in Rhode Island reported similar findings (227).
The multistate population-based study conducted during 
2003–2004 also identified a greater-than-expected number 
of cases of early-onset GBS occurring among infants born to 
women with negative prenatal screening results (61% observed 
compared with 23%–46% expected cases of early-onset GBS 
disease among full-term infants) (102). Some false-negative 
results are expected because culture is not perfectly sensitive and 
GBS can be acquired by the mother during the period between 
screening and delivery. However, the high proportion of cases 
born to women with negative screening results suggests possible 
problems in the steps required to identify GBS colonization. 
Suboptimal specimen collection timing, methods, transport, 
and/or laboratory processing might be contributing factors. 
FIGURE 3. Percentage of women with an indication who received intrapartum antibiotic 
prophylaxis — Active Bacterial Core surveillance areas, 1998–1999 and 2003–2004*
Source: Van Dyke MK, Phares CR, Lynfield R, Thomas AR, Arnold KE, Craig AS, et al. Evaluation of universal 
antenatal screening for group B Streptococcus. N Engl J Med 2009;360:2626–36.
* Reported values are weighted to account for the stratified survey design. The number of charts abstracted 
was 5,144 for 1998–1999 and 7,691 for 2003–2005.
† 95% confidence inerval.




















Tennessee California Oregon Minnesota New York Georgia Connecticut Maryland Colorado New Mexico
†
§ §
Among screened women, the date of 
the antenatal screening test was missing 
from 36% of labor and delivery charts. 
Documentation of the date allows for 
an assessment of whether screening was 
performed during the recommended 
gestation time window.
trends in neonatal GBS 
Disease
Incidence of invasive early-onset GBS 
disease has declined approximately 
80% (Figure 1) since the early 1990s, 
when implementation of intrapartum 
antibiotic prophylaxis to prevent GBS 
disease began. Nationally representative 
hospital discharge diagnostic code data 
also demonstrated a steady decrease in 
clinical sepsis rates during 1990–2002, 
with a marked decline in clinical sepsis 
among term infants during the 2 years 
following the issuance of the 1996 GBS 
prevention guidelines (228); these data 
suggest that the observed decline in early-onset GBS disease is a 
result of prevented cases of illness and not simply of sterilization 
of neonatal blood cultures as a result of exposure to maternal 
antibiotics. During 1999–2001, incidence of early-onset GBS 
disease achieved a plateau of approximately 0.5 cases per 1,000 
live births. After the 2002 guidelines were issued, incidence 
declined further and in recent years has ranged from 0.3 to 0.4 
cases per 1,000 live births. This additional decline of 20%–40% 
is consistent with that predicted for the transition from the 
1996 prevention strategy to the universal screening approach 
recommended in 2002 (62). Similar trends have been reported 
among infants delivered in all U.S. military hospitals (229). 
However, the disparity in early-onset GBS disease incidence 
between black and white infants has persisted (Figure 4) and 
is evident among both term and preterm infants (18,20). 
Preliminary surveillance data from 2008 suggest that the 
racial disparity was reduced somewhat in 2008 (30). Incidence 
among all black infants declined to 0.49 cases per 1,000 live 
births, showing progress towards the Healthy People 2010 
objective of 0.5 cases per 1,000 live births for all racial and 
ethnic groups (230). However final data from 2008, includ-
ing enhanced race/ethnicity reporting on cases and the 2008 
live birth denominators, and more years of data are needed to 
determine whether this trend is sustained.
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trends in non-GBS 
Pathogens
Decreases in the incidence of early-onset 
GBS sepsis have not been accompanied 
by increases in incidence of early-onset 
sepsis caused by other pathogens, includ-
ing those that are antimicrobial-resistant. 
Most studies, including population-based 
multicenter studies, have found stable 
(231–239) or decreasing (240,241) rates 
of non-GBS early-onset sepsis during a 
period of increasing use of intrapartum 
antibiotic prophylaxis for GBS. Increases 
in invasive Escherichia coli infections have 
been reported among preterm and low-
birth-weight or very low-birth-weight 
infants (242–246), and some studies 
have found an increasing proportion of 
ampicillin-resistant isolates among pre-
term or very low birth-weight infants with 
E. coli sepsis (235,245,247). However, the 
trends have not been consistent over time 
or across studies. A multicenter study of sepsis in preterm infants 
that reported an increase in E. coli incidence from 1991–1993 
to 1998–2000 (246) found stable rates of E. coli sepsis from 
1998–2000 to 2002–2003 and reported no significant change 
in the proportion of E. coli isolates that were resistant to ampicil-
lin (248). Whether any observed increase in ampicillin-resistant 
E. coli is attributable to the use of intrapartum antibiotics for 
GBS prophylaxis is unclear because ampicillin resistance among 
E. coli isolates has increased communitywide (249). Currently 
available evidence does not suggest any increase in non-GBS 
early-onset sepsis among term infants.
An association between intrapartum antibiotic exposure and 
ampicillin resistance in newborns with E. coli or other non-GBS 
early-onset sepsis has been observed in several studies among all 
newborns (55,239,242,250–252) and among preterm or very 
low birth-weight infants (245,246). However, studies using 
infants infected with nonresistant pathogens as a control group 
do not account for ampicillin-susceptible infections prevented 
by intrapartum antibiotic prophylaxis and therefore might 
overestimate an association between antibiotic exposure and 
antibiotic resistance (253). A multicenter case-control study of 
early-onset E. coli cases that enrolled uninfected infants born at 
the same hospitals found no association between intrapartum 
antibiotic prophylaxis exposure and infection with ampicillin-
resistant E. coli (254).
The reported increases in E. coli early-onset sepsis among 
preterm infants and antibiotic-resistant early-onset infections 
are not of sufficient magnitude to outweigh the benefits of 
intrapartum antibiotic prophylaxis to prevent early-onset GBS 
disease. Among all neonates, rates of E. coli early-onset sepsis 
have remained stable and lower than those of GBS early-onset 
disease, despite declines in GBS (CDC, unpublished data, 
2009). However, to ensure early detection of increases in the 
rate of disease or deaths caused by organisms other than GBS, 
continued surveillance of neonatal sepsis caused by organisms 
other than GBS is needed.
Impact of GBS Prevention Efforts 
on Infant Management
Provider surveys conducted in the early to mid 1990s indi-
cated that pediatricians and neonatologists were more likely to 
conduct diagnostic evaluations and initiate empiric antibiotics 
for an infant whose mother received intrapartum antibiotic 
prophylaxis than they were for an infant whose mother who did 
not receive prophylaxis (197–199). Results of studies conducted 
during 1996–2002 were inconsistent, reporting increased (255), 
stable (256), or decreased (257) use of health services (includ-
ing diagnostic tests, antibiotics, and/or length of hospital stay) 
for neonates born to women receiving intrapartum antibiotics. 
No studies have reported on the impact of the 2002 guidelines 
FIGURE 4. Incidence of early-onset invasive group B streptococcal disease, stratified by 
race and term — Active Bacterial Core surveillance areas, 2000–2007
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on health-care services for neonates. Continued monitoring 
of the influence of GBS prevention recommendations on the 
management of newborns is needed.
Recommendations
The following updated recommendations for the prevention 
of early-onset GBS disease are based on critical appraisal of 
data that have become available since publication of previous 
CDC (13,15) and ACOG (258) recommendations and replace 
previous recommendations from CDC. These recommenda-
tions have been endorsed by ACOG, AAP, ACNM, AAFP, and 
ASM. After each recommendation, its strength (indicated by 
a letter) and the quality of supporting evidence (indicated by 
a Roman numeral) are shown in parentheses according to the 
evidence-based rating system used (Table 1).
Obstetric and neonatal health-care providers, in conjunction 
with supporting laboratories and labor and delivery facilities, 
should adopt the following recommendations for the preven-
tion of early-onset GBS disease.
Identification of Candidates for 
Intrapartum Antibiotic Prophylaxis
Universal Screening for GBS
Candidates to receive intrapartum antibiotic prophylaxis to 
prevent early-onset GBS disease should be identified according 
to the indications and nonindications provided (Table 3).
The following are key components of the screening 
strategy:
•	Women	with	GBS	isolated	from	the	urine	at	any	time	dur-
ing the current pregnancy or who had a previous infant with 
invasive GBS disease should receive intrapartum antibiotic 
prophylaxis and do not need third trimester screening for 
GBS colonization (AII). Women with symptomatic or 
asymptomatic GBS urinary tract infection detected during 
pregnancy should be treated according to current standards 
of care for urinary tract infection during pregnancy and 
should receive intrapartum antibiotic prophylaxis to prevent 
early-onset GBS disease (AIII).
•	 All	 other	 pregnant	women	 should	 be	 screened	 at	 35–37	
weeks’ gestation for vaginal and rectal GBS colonization 
(AII).
•	 At	the	time	of	labor	or	rupture	of	membranes,	intrapartum	
antibiotic prophylaxis should be given to all pregnant women 
who tested positive for GBS colonization (AII), except in 
the instance of cesarean delivery performed before onset of 
labor on a woman with intact amniotic membranes.
•	 For	circumstances	in	which	screening	results	are	not	avail-
able at the time of labor and delivery, intrapartum antibiotic 
prophylaxis should be given to women who are <37 weeks 
and 0 days’ gestation, have a duration of membrane rupture 
≥18 hours, or have a temperature of ≥100.4º F (≥38.0ºC) 
(AII).
•	 In	the	absence	of	GBS	urinary	tract	infection,	antimicrobial	
agents should not be used before the intrapartum period to 
eradicate GBS genitorectal colonization, because such treat-
TABLE 3. Indications and nonindications for intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal (GBS) disease
Intrapartum GBS prophylaxis indicated Intrapartum GBS prophylaxis not indicated
•	 Previous	infant	with	invasive	GBS	disease •	 Colonization	with	GBS	during	a	previous	pregnancy	(unless	an	indication	for	
GBS prophylaxis is present for current pregnancy)
•	 GBS	bacteriuria	during	any	trimester	of	the	current	pregnancy* •	 GBS	bacteriuria	during	previous	pregnancy	(unless	an	indication	for	GBS	
prophylaxis is present for current pregnancy)
•	 Positive	GBS	vaginal-rectal	screening	culture	in	late	gestation† during 
current pregnancy*
•	 Negative	vaginal	and	rectal	GBS	screening	culture	in	late	gestation† during the 
current pregnancy, regardless of intrapartum risk factors
•	 Unknown	GBS	status	at	the	onset	of	labor	(culture	not	done,	incomplete,	
or results unknown) and any of the following:
– Delivery at <37 weeks’ gestation§
– Amniotic membrane rupture ≥18 hours
– Intrapartum temperature ≥100.4°F (≥38.0°C)¶
– Intrapartum NAAT** positive for GBS
•	 Cesarean	delivery	performed	before	onset	of	labor	on	a	woman	with	intact	
amniotic membranes, regardless of GBS colonization status or gestational age
Abbreviation: NAAT = Nucleic acid amplification tests
 * Intrapartum antibiotic prophylaxis is not indicated in this circumstance if a cesarean delivery is performed before onset of labor on a woman with intact amniotic 
membranes.
 † Optimal timing for prenatal GBS screening is at 35–37 weeks’ gestation.
 § Recommendations for the use of intrapartum antibiotics for prevention of early-onset GBS disease in the setting of threatened preterm delivery are presented in 
Figures 5 and 6.
 ¶ If amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be active against GBS should replace GBS prophylaxis.
 ** NAAT testing for GBS is optional and might not be available in all settings. If intrapartum NAAT is negative for GBS but any other intrapartum risk factor (delivery at <37 
weeks’ gestation, amniotic membrane rupture at ≥18 hours, or temperature ≥100.4°F [≥38.0°C]) is present, then intrapartum antibiotic prophylaxis is indicated.
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ment is not effective in eliminating carriage or preventing 
neonatal disease and can cause adverse consequences (DI).
•	 Intrapartum	antibiotic	prophylaxis	 to	prevent	 early-onset	
GBS disease is not recommended as a routine practice for 
cesarean deliveries performed before labor onset on women 
with intact amniotic membranes, regardless of the GBS 
colonization status of the woman or the gestational age of 
the pregnancy (CIII). The use of perioperative prophylactic 
antibiotics to prevent infectious complications of cesarean 
delivery should not be altered or affected by GBS status. 
Women expected to undergo cesarean deliveries should 
undergo routine vaginal and rectal screening for GBS at 
35–37 weeks’ gestation because onset of labor or rupture of 
membranes can occur before the planned cesarean delivery, 
and under those circumstances GBS-colonized women 
should receive intrapartum antibiotic prophylaxis (AII).
•	 Health-care	providers	should	inform	women	of	their	GBS	
screening test result and the recommended interventions 
(BIII).
The following key changes were made from the 2002 
guidelines:
•	 Guidance	 regarding	 cesarean	deliveries	 performed	before	
onset of labor on a woman with intact amniotic membranes 
is clarified as applying to cesarean deliveries performed at 
any gestational age (CIII).
•	 In	settings	in	which	NAAT	for	GBS	is	available,	obstetric	
providers can choose to perform intrapartum testing of vagi-
nal-rectal samples from women with unknown GBS coloni-
zation status and no intrapartum risk factors (temperature of 
≥100.4º F [≥38.0ºC] or rupture of amniotic membranes ≥18 
hours) at the time of testing and who are delivering at term 
(CII). If an intrapartum risk factor subsequently develops, 
antibiotic prophylaxis should be administered regardless of 
the intrapartum testing results (AIII).
•	Women	with	positive	intrapartum	NAAT	results	for	GBS	
should receive antibiotic prophylaxis (AII). NAAT testing 
is optional and might not be available in all settings.
threatened Preterm Delivery
Women admitted with signs and symptoms of preterm 
labor (before 37 weeks and 0 days’ gestation) should be man-
aged according to the algorithm provided (Figure 5). Women 
with rupture of membranes at <37 weeks and 0 days’ gesta-
tion should be managed according to the algorithm provided 
(Figure 6).
The following are key components of threatened preterm 
delivery GBS management:
•	Women	admitted	with	signs	and	symptoms	of	labor	or	with	
rupture of membranes at <37 weeks and 0 days’ gestation 
should be screened for GBS colonization at hospital admis-
sion unless a vaginal-rectal GBS screen was performed within 
the preceding 5 weeks (AII).
•	Women	admitted	with	signs	and	symptoms	of	preterm	labor	
who have unknown GBS colonization status at admission or 
a positive GBS screen within the preceding 5 weeks should 
receive GBS prophylaxis at hospital admission (AII).
•	 Antibiotics	 given	 for	GBS	prophylaxis	 to	 a	woman	with	
preterm labor should be discontinued immediately if at any 
FIGURE 5. Algorithm for screening for group B streptococcal (GBS) 
colonization and use of intrapartum prophylaxis for women with 
preterm* labor (PTL)
 * At <37 weeks and 0 days’ gestation.
 † If patient has undergone vaginal-rectal GBS culture within the preceding 5 
weeks, the results of that culture should guide management. GBS-colonized 
women should receive intrapartum antibiotic prophylaxis. No antibiotics are 
indicated for GBS prophylaxis if a vaginal-rectal screen within 5 weeks was 
negative.
 § See Figure 8 for recommended antibiotic regimens.
 ¶ Patient should be regularly assessed for progression to true labor; if the 
patient is considered not to be in true labor, discontinue GBS prophylaxis.
 ** If GBS culture results become available prior to delivery and are negative, 
then discontinue GBS prophylaxis.
 †† Unless subsequent GBS culture prior to delivery is positive.
 §§ A negative GBS screen is considered valid for 5 weeks. If a patient with a history 
of PTL is re-admitted with signs and symptoms of PTL and had a negative GBS 
screen >5 weeks prior, she should be rescreened and managed according to 
this algorithm at that time.
Patient entering true labor?¶
Continue GBS prophylaxis
until delivery**
Not available prior to labor 
onset and patient still preterm
Patient  admitted with signs and symptoms of preterm labor
NoYes
Obtain GBS culture results 
NegativePositive
GBS prophylaxis 
at onset of true labor
No GBS prophylaxis at onset of true 
labor;†† repeat vaginal-rectal culture 
if patient reaches 35–37 weeks’ 
gestation and has not yet delivered§§
Obtain vaginal-rectal swab for GBS culture† and start GBS prophylaxis§
Discontinue GBS 
prophylaxis
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FIGURE 6. Algorithm for screening for group B streptococcal (GBS) 
colonization and use of intrapartum prophylaxis for women with 
preterm* premature rupture of membranes (pPROM)
 * At <37 weeks and 0 days’ gestation. 
 † If patient has undergone vaginal-rectal GBS culture within the preceding 5 
weeks, the results of that culture should guide management. GBS-colonized 
women should receive intrapartum antibiotic prophylaxis. No antibiotics are 
indicated for GBS prophylaxis if a vaginal-rectal screen within 5 weeks was 
negative.
 § Antibiotics given for latency in the setting of pPROM that include ampicillin 
2 g intravenously (IV) once, followed by 1 g IV every 6 hours for at least 48 
hours are adequate for GBS prophylaxis. If other regimens are used, GBS 
prophylaxis should be initiated in addition.
 ¶ See Figure 8 for recommended antibiotic regimens.
 ** GBS prophylaxis should be discontinued at 48 hours for women with pPROM 
who are not in labor. If results from a GBS screen performed on admission 
become available during the 48-hour period and are negative, GBS prophy-
laxis should be discontinued at that time. 
 †† Unless subsequent GBS culture prior to delivery is positive.
 §§ A negative GBS screen is considered valid for 5 weeks. If a patient with pPROM 
is entering labor and had a negative GBS screen >5 weeks prior, she should 




Continue antibiotics per standard 
of care if receiving for latency  
or
continue antibiotics for 48 hours**
 if receiving for GBS prophylaxis
Not available prior 
to labor onset
Obtain vaginal-rectal swab for GBS culture† and start 
antibiotics for latency§ or GBS prophylaxis¶
NoYes
Obtain GBS culture results 
NegativePositive
GBS prophylaxis at 
onset of true labor
No GBS prophylaxis at onset of true 
labor;†† repeat vaginal-rectal culture 
if patient reaches 35–37 weeks’ 
gestation and has not yet delivered§§
point it is determined that she is not in true labor or if the 
GBS culture at admission is negative (AII).
•	 Negative	GBS	 colonization	 status	 should	 not	 affect	 the	
administration of antibiotics for other indications (AIII).
•	Women	with	threatened	preterm	delivery	who	have	a	GBS	
screen performed that is positive and do not deliver at that 
time should receive GBS prophylaxis when true labor begins 
(AII).
•	Women	with	threatened	preterm	delivery	who	have	a	GBS	
screen performed that is negative but do not deliver at that 
time should undergo repeat screening at 35–37 weeks’ ges-
tation. If such women are re-admitted at a later date with 
threatened preterm delivery, they should undergo repeat 
screening if the previous culture was performed >5 weeks 
prior (AIII).
The following key changes were made from the 2002 
guidelines:
•	 Separate	algorithms	are	presented	for	GBS	prophylaxis	in	the	
setting of threatened preterm delivery, one for spontaneous 
preterm labor (Figure 5) and one for preterm premature 
rupture of membranes (Figure 6).
•	 GBS	prophylaxis	provided	to	women	with	signs	and	symp-
toms of preterm labor should be discontinued if it is deter-
mined that the patient is not in true labor (AI).
•	 Antibiotics	given	to	prolong	latency	for	preterm	premature	
rupture of membranes with adequate GBS coverage (specifi-
cally 2 g ampicillin administered intravenously followed by 
1 g administered intravenously every 6 hours for 48 hours) 
are sufficient for GBS prophylaxis if delivery occurs while the 
patient is receiving that antibiotic regime (CIII). Oral anti-
biotics alone are not adequate for GBS prophylaxis (DII).
•	Women	with	 preterm	premature	 rupture	 of	membranes	
who are not in labor and are receiving antibiotics to prolong 
latency with adequate GBS coverage should be managed 
according to standard of care for preterm premature rupture 
of membranes; GBS testing results should not affect the 
duration of antibiotics (BIII).
•	Women	with	preterm	premature	rupture	of	membranes	who	
are not in labor and are not receiving antibiotics to prolong 
latency (or are receiving antibiotics that do not have adequate 
GBS coverage) should receive GBS prophylaxis for 48 hours, 
unless a GBS screen performed within the preceding 5 weeks 
was negative (CIII). If the results from a GBS screen per-
formed on admission become available during that 48-hour 
period and are negative, then GBS prophylaxis should be 
discontinued at that time.
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GBS Specimen Collection 
and Processing
GBS specimen collection and processing should be 
conducted according to the recommendations provided 
(Boxes 1–3 and Figure 7).
The following are key components of specimen collection 
and processing:
•	 GBS	colonization	status	should	be	determined	by	collecting	
both vaginal and rectal specimens at 35–37 weeks’ gestation. 
A single combined vaginal-rectal specimen can be collected 
(AII). 
•	 Specimens	 should	 undergo	 18–24	 hour	 incubation	 at	
35°–37°C in an appropriate enrichment broth medium to 
enhance the recovery of GBS (AI).
•	 Accurate	results	are	more	important	than	rapid	turnaround	
time for antenatal screening (AIII).
•	 To	 ensure	 proper	 testing	 of	 specimens,	 clinicians	must	
inform laboratories when submitted urine specimens are 
from pregnant women (AIII).
•	 Antimicrobial	 susceptibility	 testing	 should	 be	 performed	
on antenatal GBS isolates from penicillin-allergic women 
at high risk for anaphylaxis because of a history of anaphy-
laxis, angioedema, respiratory distress, or urticaria follow-
ing administration of a penicillin or a cephalosporin. (AII) 
(Box 3).





identification from chromogenic media and identification 
directly from enriched broth. NAAT, such as commercially 
available PCR assays, can also be used after enrichment, if 
laboratories have validated NAAT performance and insti-
tuted appropriate quality controls (CII).
•	 A	 direct	 plating	 option	 can	 be	 included	 in	 addition	 to	
enriched culture (CII). Direct plating has a lower sensitivity 
than enriched culture and should not be used as sole means 
to identify GBS.
•	 Testing	 for	 inducible	 clindamycin	 resistance	 should	 be	
performed on antenatal GBS isolates that are susceptible to 
clindamycin, resistant to erythromycin, and are from penicillin-
allergic women at high risk for anaphylaxis (CIII).
•	 Laboratories	should	report	GBS	in	urine	culture	specimens	
when present at concentrations of ≥104 colony-forming 
units/ml in pure culture or mixed with a second microorgan-
ism (AII) (Box 4).
Intrapartum Antibiotic Prophylaxis
Intrapartum antibiotic prophylaxis agents and dosing should 
be administered according to the recommendations provided 
(Figure 8).
The following are key components of intrapartum antibiotic 
prophylaxis agents and dosing:
•	 Penicillin	remains	the	agent	of	choice	for	intrapartum	antibi-
otic prophylaxis, with ampicillin as an acceptable alternative 
(AI).
•	 Penicillin-allergic	women	who	 do	 not	 have	 a	 history	 of	
anaphylaxis, angioedema, respiratory distress or urticaria 
following administration of a penicillin or a cephalosporin 
should receive cefazolin (BII).
•	 Antimicrobial	 susceptibility	 testing	should	be	ordered	 for	
antenatal GBS cultures performed on penicillin-allergic 
women at high risk for anaphylaxis because of a history of 
anaphylaxis, angioedema, respiratory distress or urticaria 
BOX 1. Procedures for collecting clinical specimens for culture of 
group B Streptococcus (GBS) at 35–37 weeks’ gestation
•	 Swab	the	lower	vagina	(vaginal	introitus),	followed	by	
the rectum (i.e., insert swab through the anal sphincter) 
using the same swab or two different swabs. Cultures 
should be collected in the outpatient setting by the 
health-care provider or, with appropriate instruction, 
by the patient herself. Cervical, perianal, perirectal or 
perineal specimens are not acceptable, and a speculum 
should not be used for culture collection.
•	 Place	 the	 swab(s)	 into	 a	 nonnutritive	 transport	
medium. Appropriate transport systems (e.g., Stuart’s 
or Amies with or without charcoal) are commercially 
available. GBS isolates can remain viable in transport 
media for several days at room temperature; however 
the recovery of isolates declines over one to four days, 
especially at elevated temperatures, which can lead to 
false-negative results. When feasible, specimens should 
be refrigerated before processing.
•	 Specimen	 requisitions	 should	 indicate	 clearly	 that	
specimens are for group B streptococcal testing. 
Patients who state that they are allergic to penicil-
lin should be evaluated for risk for anaphylaxis. If 
a woman is determined to be at high risk for ana-
phylaxis,* susceptibility testing for clindamycin and 
erythromycin should be ordered.
* Patients with a history of any of the following after receiving penicillin 
or a cephalosporin are considered to be at high risk for anaphylaxis: 
anaphylaxis, angioedema, respiratory distress, or urticaria.
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•	 Remove	 swab(s)	 from	 transport	medium.*	 Inoculate	
swab(s) into a recommended selective broth medium, 
such as Todd-Hewitt broth supplemented with either 
gentamicin (8 µg/ml) and nalidixic acid (15 µg/ml) 
[TransVag broth], or with colistin (10 µg/ml) and nali-
dixic acid (15 µg/ml) [Lim broth]. TransVag broth may 
be supplemented with 5% defibrinated sheep blood to 
increase the recovery of GBS.† As an alternative, swabs 
may be inoculated into selective enrichment broth that 
incorporates chromogenic pigments for the detection 
of beta-hemolytic GBS using color detection. Examples 
of appropriate commercially available options include 
StrepB carrot broth or Granada Biphasic broth.§
•	 Incubate	 inoculated	 selective	 broth	 for	 18–24	 hours	
35°–37°C in ambient air or 5% CO2.
•	 For	TransVag	 or	Lim	broth,	 subculture	 the	 incubated	
broth to an appropriate agar plate (e.g., tryptic soy agar 
with 5% defibrinated sheep blood, Colombia agar with 
colistin and nalidixic acid, or a commercial chromogenic 
agar). For chromogenic broth, monitor for color change 
indicative of GBS per product instructions. GBS 
detection using chromogenic broth is possible only for 
beta-hemolytic strains,¶ and therefore all broths that are 
negative (i.e., no color detection) should be subcultured 
to a sheep blood agar plate with 5% sheep blood or tested 
for GBS antigen or by DNA probe to further identify 
nonhemolytic GBS strains.
•	 Inspect	agar	plates	and	identify	organisms	suggestive	of	
GBS (e.g., narrow zone of beta hemolysis on blood agar, 
gram-positive cocci, catalase-negative, and/or hippurate-
positive). Note that hemolysis can be difficult to observe, 
so typical colonies without hemolysis should also be 
further tested. If GBS is not identified after incubation 
for 18–24 hours, then reincubate plates overnight and 
examine for suspected GBS colonies.
•	 Various	streptococcal	grouping	latex	agglutination	tests	
or other tests for GBS detection (e.g., GBS Accuprobe) 
may be used for specific identification, or the CAMP test 
can be employed for presumptive identification.
•	 Optional	direct	broth	testing:**	Detection	of	GBS	can	
be determined directly from broth media using latex 
agglutination, probes or nucleic acid amplification tests 
(NAAT) such as PCR.
BOX 2. Procedures for processing clinical specimens for culture of group B Streptococcus (GBS) (see Figure 7)
 * Before the inoculation step, laboratories may choose to roll the vaginal-rectal swab(s) on a blood agar plate with or without colistin and nalidixic acid or 
commercially available chromogenic agar (appropriate recommendations include chromID Strepto B [which might detect both hemolytic and nonhemolytic 
GBS] or Granada Agar [which detects hemolytic GBS]. Source: Tazi A, Réglier-Poupet H, Dautezac F, Raymond J, Poyart C. Comparative evaluation of 
Strepto B ID chromogenic medium and Granada media for the detection of group B Streptococcus from vaginal samples of pregnant women. J Microbiol 
Methods 2008;73:263–5). This approach should be taken only in addition to, and not instead of, inoculation into selective broth. The directly inoculated 
blood agar plate should be streaked for isolation, incubated at 35°–37°C in ambient air or 5% CO2 for 18–24 hours and inspected for organisms suggestive 
of GBS as described above. If suspected colonies are confirmed as GBS, the selective broth can be discarded, thus shortening the time to obtaining culture 
results. The directly inoculated chromogenic agar should be streaked for isolation and incubated at 35°–37°C for 18–24 hours. Hemolytic GBS isolates are 
identified by colored colonies as directed by specific manufacturers’ instructions, and selective broth can be discarded if GBS positive. 
 † Source: Fenton LJ, Harper MH. Evaluation of colistin and nalidixic acid in Todd-Hewitt broth for selective isolation of groupB streptococci. J Clin Microbiol 
1979;9:167–9. Although Trans-Vag medium often is available without sheep blood, direct comparison of medium with and without sheep blood has shown 
higher yield when blood is added. Lim broth also might benefit from the addition of sheep blood, although the improvement in yield is smaller, and sufficient 
data are not yet available to support a recommendation.
 § Sources: Church DL, Baxter H, Lloyd T, Miller B, Elsayed S. Evaluation of StrepB carrot broth versus Lim broth for detection of group B Streptococcus 
colonization status of near-term pregnant women. J Clin Microbiol 2008;46:2780–2. Martinho F, Prieto E, Pinto D, Castro RM, Morais AM, Salgado L, 
Exposto Fda L. Evaluation of liquid biphasic Granada medium and instant liquid biphasic Granada medium for group B Streptococcus detection. Enferm 
Infecc Microbiol Clin 2008;26:69–71.
 ¶ Source: de la Rosa M, Perez M, Carazo C, Pareja L, Peis JI, Hernandez F. New Granada medium for detection and identification of group B streptococci. 
J Clin Microbiol 1992;30:1019–21.
 ** Direct latex agglutination, probe detection or nucleic acid amplification testing on enriched selective broth is an additional option. Sources: Guerrero C, 
Martinez J, Menasalvas A, Blazquez R, Rodriguez, Segovia M. Use of direct latex agglutination testing of selective broth in the detection of group B streptococcal 
carriage in pregnant women. Eur J Clin Microbiol Infect Dis 2004;23:61–2. Goodrich JS, Miller MB. Comprison of culture and 2 real-time polymerase 
chain reaction assays to detect group B Streptococcus during antepartum screening. Diagn Microbiol Infect Dis 2007;59:17–22. Block T, Munson E, Culver 
A, Vaughan K, Hryciuk JE. Comparison of carrot broth- and selective Todd-Hewitt broth-enhanced PCR protocols for real-time detection of Streptococcus 
agalactiae in prenatal vaginal/anorectal specimens. J Clin Microbiol 2008;46:3615–20. Montague NS, Cleary TJ, Martinez OV, Procop GW. Detection of 
group B streptococci in Lim broth by use of group B Streptococcus peptide nucleic acid fluorescent in situ hybridization and selective and nonselective agars. 
J Clin Microbiol 2008 46:3470–2. If a rapid test performed on enriched broth yields positive results and antimicrobial susceptibility testing is recommended 
(for penicillan-allergic women at high risk for anaphylaxis), the enriched broth should be subcultured to obtain an isolate.
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following administration of a penicillin or a cephalosporin 
(AII). To ensure proper testing, clinicians must inform labo-
ratories of the need for antimicrobial susceptibility testing 
in such cases (AIII).
•	 Penicillin-allergic	women	at	high	risk	for	anaphylaxis	should	
receive clindamycin if their GBS isolate is susceptible to clin-
damycin and erythromycin, as determined by antimicrobial 
susceptibility testing; if the isolate is sensitive to clindamycin 
but resistant to erythromycin, clindamycin may be used 
if testing for inducible clindamycin resistance is negative 
(CIII). Penicillin-allergic women at high risk for anaphylaxis 
should receive vancomycin if their isolate is intrinsically 
resistant to clindamycin as determined by antimicrobial 
susceptibility testing, if the isolate demonstrates inducible 
resistance to clindamycin, or if susceptibility to both agents 
is unknown (CIII) (Box 3).
The following key changes were made from the 2002 
guidelines:
•	The	definition	 of	 high	 risk	 for	 anaphylaxis	 is	 clarified	 as	
a history of anaphylaxis, angioedema, respiratory distress 
or urticaria following administration of a penicillin or a 
cephalosporin.
•	The	recommended	dosing	regimen	of	penicillin	G	is	5	mil-
lion units intravenously, followed by 2.5–3.0 million units 
intravenously every 4 hours (AII). The range of 2.5–3.0 mil-
lion units is recommended to achieve adequate drug levels 
in the fetal circulation and amniotic fluid while avoiding 
neurotoxicity. The choice of dose within that range should 
be guided by which formulations of penicillin G are read-
ily available in order to reduce the need for pharmacies to 
specially prepare doses.
•	The	Clinical	and	Laboratory	Standards	Institute	(CLSI)	
recommends disk diffusion or broth microdilution testing 
for susceptibility testing of GBS.* Commercial systems 
that have been cleared or approved for testing of strep-
tococci other than S. pneumoniae also may be used. 
•	 To	ensure	accurate	 results,	 laboratories	 should	 include	
a test for detection of inducible clindamycin resistance. 
The double-disk diffusion method (D-zone test) is 
recommended for testing erythromycin-resistant and 
clindamycin-susceptible GBS.† Other validated tests to 
detect inducible clindamycin resistance in GBS may be 
used in place of the D-zone test.
•	 Use	a	cotton	swab	to	make	a	suspension	from	18–24	hour	
growth of the organism in saline or Mueller-Hinton broth 
equal to a 0.5 McFarland turbidity standard.
•	Within	15	minutes	of	adjusting	the	turbidity	at	room	
temperature, dip a sterile cotton swab into the adjusted 
suspension. The swab should be rotated several times and 
pressed firmly on the inside wall of the tube above the 
fluid level. Use the swab to inoculate the entire surface 
of a plate of Mueller-Hinton agar with 5% sheep blood. 
After the plate is dry, use sterile forceps to place a clin-
damycin (2 µg) disk and an erythromycin (15 µg) disk 
12 mm apart for D-zone testing (Note: This differs from 
recommended 15–26 mm for staphylococci and a disk 
dispenser cannot be used to place disks on the plate for 
streptococci testing). 
•	 Incubate	inoculated	agar	plate	at	35⁰C in 5% CO2 for 
20–24 hours.
•	 Isolates	with	 blunting	 of	 the	 inhibition	 zone	 around	
the clindamycin disk adjacent to the erythromycin disk 
(D-zone positive) should be considered to have inducible 
clindamycin resistance and are presumed to be resistant. 
(Note: Other validated tests to detect GBS with inducible 
clindamycin resistance may be used.) 
•	The	following	comment	could	be	included	in	patient	reports	
for isolates that show inducible clindamycin resistance: 
“This isolate is presumed to be resistant on the basis of 
detection of inducible clindamycin resistance. Clindamycin 
still might be effective clinically in some cases.”
BOX 3. Procedures for clindamycin and erythromycin susceptibility testing of group B streptococcal (GBS) isolates, when ordered for 
penicillin-allergic patients
* Source: Clinical and Laboratory Standards Institute. Performance standard for antimicrobial susceptibility testing, M100-S20, Table 2H-1, Wayne, Pa: 
Clinical and Laboratory Standards Institute; 2010. CLSI recommends disk diffusion (M-2) or broth microdilution testing (M-7) for susceptibility testing 
of GBS. Commercial systems that have been cleared or approved for testing of streptococci other than S. pneumoniae may also be used. Interpret according 
to CLSI guidelines for Streptococcus spp. Beta-hemolytic Group (2010 breakpoints for disk-diffusion: for clindamycin: ≥19 mm = susceptible, 16–18 mm = 
intermediate, and ≤15 mm = resistant; for erythromycin: ≥21 mm = susceptible, 16–20 mm = intermediate, and ≤15 = resistant; for broth microdilution: 
clindamycin: ≤0.25 µg/ml = susceptible, 0.5 µg/ml = intermediate, and ≥1.0 µg/ml = resistant; and for erythromycin: ≤0.25 µg/ml = susceptible, 0.5 µg/ml = 
intermediate, and ≥1.0 µg/ml = resistant).
† Sources: Tang P, Ng P, Lum M, et al. Use of the Vitek-1 and Vitek-2 systems for detection of constitutive and inducible macrolide resistance in Group B 
streptococci. J Clin Microbiol 2004;42:2282–4. Richter SS, Howard WJ, Weinstein MP, et al. Multicenter evaluation of the BD Phoenix automated microbiology 
system for antimicrobial susceptibility testing of Streptococcus species. J Clin Microbiol 2008;45:2863–71.
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•	 Erythromycin	 is	 no	 longer	 an	 acceptable	 alternative	 for	
intrapartum GBS prophylaxis for penicillin-allergic women 
at high risk for anaphylaxis.
other obstetric Management Issues
•	 Available	data	are	not	sufficient	to	suggest	that	GBS	coloni-
zation should differentially affect the use of obstetric proce-
dures for monitoring, cervical ripening or labor induction. 
These procedures should be reserved for appropriate indica-
tions and not altered for GBS-colonized women (CIII).
•	 Data	are	not	sufficient	to	make	recommendations	regarding	
the timing of procedures intended to facilitate progression 
of labor, such as amniotomy, in GBS-colonized women. 
Intrapartum antibiotic prophylaxis is optimal if administered 
FIGURE 7. Algorithm for recommended laboratory testing for prenatal screening for group B streptococcal (GBS) colonization*
* See Boxes 1–3 for details on specimen processing and antimicrobial susceptibility testing.
† Direct plating with appropriate media may be done in addition to enriched culture. Direct plating should not be used as the sole means to identify GBS.
Vaginal-rectal swab†
Enrichment broth (can use nonigmented or pigmented broth)
Incubate 18–24 hrs at  35°–37°C
Subculture to appropriate media; 
incubate 18–24 hrs at 35°–37°C
DNA probe, latex agglutination or 
nucleic acid amplication test (NAAT)
Nonpigmented broth Pigmented broth 
Further testing (can 
subculture or use 
rapid tests) No indicator color growth GBS indicator color observed 










Antimicrobial susceptibility testing if penicillin-allergic and at high risk for anaphylaxis*
Report as GBS+
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for at least 4 hours before delivery; therefore, such procedures 
should be timed accordingly, if possible (CIII).
•	 No	medically	 necessary	 obstetric	 procedure	 should	 be	




To detect potential sepsis cases in newborns as early as pos-
sible, newborns should be managed according to the algorithm 
provided (Figure 9).The following are 
key components of the neonatal man-
agement algorithm:
•	 Any	 newborn	with	 signs	 of	 sepsis	
should receive a full diagnostic evalu-
ation and receive antibiotic therapy 
pending the results of the evaluation. 
The evaluation should include a blood 
culture; a CBC including white blood 
cell differential and platelet count; 
a chest radiograph if any abnormal 
respiratory signs are present; and a 
lumbar puncture if the newborn is 
stable enough to tolerate the procedure 
and sepsis is suspected. Therapy for the 
infant should include antimicrobial 
agents active against GBS (including 
intravenous ampicillin) as well as other 
organisms that might cause neonatal 
sepsis, such as E. coli (AII).
•	Well-appearing	newborns	whose	moth-
ers had suspected chorioamnionitis 
should undergo a limited evaluation 
and receive antibiotic therapy pending 
culture results (AII). The evaluation 
should include a blood culture and a 
CBC including white blood cell dif-
ferential and platelet count; no chest 
radiograph or lumbar puncture is 
needed. Consultation with obstetric 
providers to assess whether chorioam-
nionitis was suspected is important 
to determine neonatal management 
(CIII).
•	Well-appearing	infants	whose	moth-
ers had no chorioamnionitis and 
no indication for GBS prophylaxis 
should be managed according to 
routine clinical care (CIII).
BOX 4. Identification of group B Streptococcus (GBS) bacteriuria in 
pregnant women
•	 Routine	 screening	 for	 asymptomatic	 bacteriuria	 is	
recommended in pregnant women, and laboratories 
should screen urine culture specimens for the presence 
of GBS in concentrations of 104 colony-forming units 
(cfu)/ml or greater. 
•	 Laboratories	 should	 identify	GBS	when	 present	 at	
≥104 cfu/ml in pure culture or mixed with a second 
microorganism.
FIGURE 8. Recommended regimens for intrapartum antibiotic prophylaxis for prevention of 
early-onset group B streptococcal (GBS) disease*
Abbreviation: IV = intravenously.
 * Broader spectrum agents, including an agent active against GBS, might be necessary for treatment of 
chorioamnionitis.
 † Doses ranging from 2.5 to 3.0 million units are acceptable for the doses administered every 4 hours fol-
lowing the initial dose. The choice of dose within that range should be guided by which formulations of 
penicillin G are readily available to reduce the need for pharmacies to specially prepare doses. 
 § Penicillin-allergic patients with a history of anaphylaxis, angioedema, respiratory distress, or urticaria 
following administration of penicillin or a cephalosporin are considered to be at high risk for anaphylaxis 
and should not receive penicillin, ampicillin, or cefazolin for GBS intrapartum prophylaxis. For penicillin-
allergic patients who do not have a history of those reactions, cefazolin is the preferred agent because 
pharmacologic data suggest it achieves effective intraamniotic concentrations. Vancomycin and clin-
damycin should be reserved for penicillin-allergic women at high risk for anaphylaxis.
 ¶ If laboratory facilities are adequate, clindamycin and erythromycin susceptibility testing (Box 3) should be 
performed on prenatal GBS isolates from penicillin-allergic women at high risk for anaphylaxis. If no suscep-
tibility testing is performed, or the results are not available at the time of labor, vancomycin is the preferred 
agent for GBS intrapartum prophylaxis for penicillin-allergic women at high risk for anaphylaxis. 
 ** Resistance to erythromycin is often but not always associated with clindamycin resistance. If an isolate is 
resistant to erythromycin, it might have inducible resistance to clindamycin, even if it appears susceptible 
to clindamycin. If a GBS isolate is susceptible to clindamycin, resistant to erythromycin, and testing for 
inducible clindamycin resistance has been performed and is negative (no inducible resistance) , then 
clindamycin can be used for GBS intrapartum prophylaxis instead of vancomycin. 
Patient allergic to penicillin?
Penicillin G, 5 million units IV initial dose, 
then 2.5–3.0 million units† every 4 hrs until delivery
or
Ampicillin, 2 g IV initial dose, 
then 1 g IV every 4 hrs until delivery
Patient with a history of any of the following 







Cefazolin, 2g IV initial dose, 
then 1 g IV every 8 hrs until delivery
Isolate susceptible to clindamycin¶ 
and erythromycin**?
YesNo
Vancomycin, 1 g IV 
every 12 hrs until delivery
Clindamycin, 900 mg IV 
every 8 hrs until delivery 
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FIGURE 9. Algorithm for secondary prevention of early-onset group 
B streptococcal (GBS) disease among newborns
 * Full diagnostic evaluation includes a blood culture, a complete blood count 
(CBC) including white blood cell differential and platelet counts, chest ra-
diograph (if respiratory abnormalities are present), and lumbar puncture (if 
patient is stable enough to tolerate procedure and sepsis is suspected).
 † Antibiotic therapy should be directed toward the most common causes of 
neonatal sepsis, including intravenous ampicillin for GBS and coverage for 
other organisms (including Escherichia coli and other gram-negative patho-
gens) and should take into account local antibiotic resistance patterns.
 § Consultation with obstetric providers is important to determine the level of 
clinical suspicion for chorioamnionitis. Chorioamnionitis is diagnosed clini-
cally and some of the signs are nonspecific. 
 ¶ Limited evaluation includes blood culture (at birth) and CBC with differential 
and platelets (at birth and/or at 6–12 hours of life). 
 ** See table 3 for indications for intrapartum GBS prophylaxis.
 †† If signs of sepsis develop, a full diagnostic evaluation should be conducted 
and antibiotic therapy initiated.
 §§ If ≥37 weeks’ gestation, observation may occur at home after 24 hours if other 
discharge criteria have been met, access to medical care is readily available, 
and a person who is able to comply fully with instructions for home observa-
tion will be present. If any of these conditions is not met, the infant should 
be observed in the hospital for at least 48 hours and until discharge criteria 
are achieved.
 ¶¶ Some experts recommend a CBC with differential and platelets at age 6–12 
hours.
Signs of neonatal sepsis? Yes Full diagnostic evaluation*
Antibiotic therapy†
Maternal chorioamnionitis?§ Yes Limited evaluation¶
Antibiotic therapy†
No
GBS prophylaxis indicated 
for mother?**
No Routine clinical care††
Mother received intravenous 
penicillin, ampicillin, 
or cefazolin for ≥4 hours 
before delivery?




≥37 weeks and duration 
of membrane rupture 
<18 hours?
Yes Observation for ≥48 hours††¶¶
No




Observation for ≥48 hours††
•	Well-appearing	infants	of	any	gestational	age	whose	mother	
received adequate intrapartum GBS prophylaxis (≥4 hours of 
penicillin, ampicillin, or cefazolin before delivery) should be 
observed for ≥48 hours, and no routine diagnostic testing is 
recommended (BIII). Such infants can be discharged home as 
early as 24 hours after delivery, assuming that other discharge 
criteria have been met, ready access to medical care exists, 
and that a person able to comply fully with instructions for 
home observation will be present (CIII).
•	 For	well-appearing	 infants	 born	 to	mothers	who	had	 an	
indication for GBS prophylaxis but received no or inadequate 
prophylaxis, if the infant is well-appearing and ≥37 weeks 
and 0 days’ gestational age and the duration of membrane 
rupture before delivery was <18 hours, then the infant should 
be observed for ≥48 hours, and no routine diagnostic testing 
is recommended (BIII). If the infant is well-appearing and 
either <37 weeks and 0 days’ gestational age or the duration 
of membrane rupture before delivery was ≥18 hours, then the 
infant should undergo a limited evaluation and observation 
for ≥48 hours (BIII).




laxis is clarified as ≥4 hours of IV penicillin, ampicillin, or 
cefazolin before delivery (AII). All other agents or dura-
tions are considered inadequate for purposes of neonatal 
management.
•	Well-appearing	infants	whose	mother	had	an	indication	for	
GBS prophylaxis but received no or inadequate intrapartum 
antibiotics can be managed with observation for ≥48 hours, 
unless the infant is <37 weeks and 0 days’ gestational age 
or membranes were ruptured ≥18 hours before delivery, in 
which case a limited evaluation and observation for ≥48 
hours is recommended (BIII).
•	Well-appearing	infants	with	a	gestational	age	of	35–36	weeks	
whose mothers received adequate intrapartum antibiotic 
prophylaxis do not routinely require diagnostic evaluations 
(CIII).
Monitoring Implementation 
and Impact of Guidelines
•	 Local	and	state	public	health	agencies,	in	conjunction	with	
appropriate groups of hospitals, are encouraged to establish 
surveillance for early-onset GBS disease and to take other 
steps to promote perinatal GBS disease prevention and edu-
cation to reduce the incidence of early-onset GBS disease 
in their states (CIII).
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burden of prenatal-onset GBS disease has not been assessed 
adequately (32,33,259–262), and no effective prevention tools 
have been identified before the intrapartum period. GBS dis-
ease among nonpregnant adults has increased in recent years. 
Although GBS vaccines might be expected to aid in reduction 
of racial disparities and prevention of invasive GBS disease 
among adults and infants (both early- and late-onset), con-
tinued exploration of other means to improve and strengthen 
GBS prevention efforts is warranted.
Until a safe and efficacious vaccine achieves licensure, con-
tinued monitoring for potential unintended consequences of 
intrapartum antibiotic chemoprophylaxis is needed, with an 
emphasis on tracking key sentinel events signaling a need for 
revision of the guidelines. Such sentinel events include the 
emergence of penicillin resistance among GBS isolates and an 
increase in the incidence of disease or deaths due to neonatal 
pathogens other than GBS that offsets the burden of early-
onset disease prevented by intrapartum antibiotic prophylaxis. 
Monitoring for the latter will require long-term surveillance of 
a large population of term and preterm births (246,248).
States are encouraged to monitor incidence of GBS disease, 
to promote activities that enhance perinatal GBS disease pre-
vention and education, and to assess progress toward national 
objectives for disease reduction, such as objectives for Healthy 
People 2010 (230) and the forthcoming Healthy People 2020 
(263). Practical tools to assist with monitoring for missed 
opportunities for perinatal GBS prevention within hospitals 
have been published (264); additional prevention information 
and tools for providers, patients and clinical microbiologists 
are available at http://www.cdc.gov/groupbstrep, http://www.
acog.org, http://www.aap.org, http://www.aafp.org, http://
www.midwife.org, and http://www.asm.org.
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